- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06500039
Positive Psychological Interventions for Patients With Multiple Sclerosis
August 21, 2024 updated by: Aliye Yaşayacak, Abant Izzet Baysal University
The Effect of Positive Psychological Interventions on Quality of Life and Well-Being in Patients With Multiple Sclerosis
This study aims to determine the effectiveness of positive psychological interventions on the quality of life and well-being levels of patients with multiple sclerosis.Two groups will be selected as intervention and control groups.
An intervention method consisting of three good things in life and gratitude activities, each lasting two weeks, was determined for the intervention group.
An activity was planned for control group participants to write their daily routines.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
People with Multiple Sclerosis (MS) face numerous physical and mental symptoms as well as emotional and social challenges.
The fact that the disease usually occurs in young adulthood, when individuals are most productive, causes disability, its unpredictable and variable nature, and the lack of a known treatment make it difficult to live with MS and accept the disease.
The physical, cognitive, behavioral and social changes that occur with the disease affect daily life activities, well-being.
and greatly affects the quality of life.
There are various interventions developed to improve the adaptation processes of individuals diagnosed with a chronic disease such as MS, to prevent and reduce psychiatric symptoms, and to increase quality of life and well-being.
One of the intervention approaches is positive psychological interventions from the field of positive psychology.
Positive psychological interventions are a psychosocial intervention method based on the systematic completion of certain activities aimed at increasing positive emotions, thoughts and behaviors.
Since the interventions focus on strengthening positive mental states rather than reducing psychological symptoms, they also have an advantage over traditional interventions in that they can be applied to both sick and non-patients.
However, it appears that positive psychological intervention studies have just begun to be implemented in patients with MS.
In our country, no study has been found using positive psychological intervention in MS patients.
This study aims to determine the effectiveness of positive psychological interventions on the quality of life and well-being levels of patients with multiple sclerosis.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bolu, Turkey, 14300
- Bolu abant Izzet Baysal University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of MS by a neurologist according to McDonald criteria
- Having at least 1 year of MS history
- Expanded Disability Status Scale (EDSS) score measured by the neurology clinic is <3.5
- Being between the ages of 18-65 being literate
- Ability to communicate in Turkish
- Volunteering to participate in the study
Exclusion Criteria:
- Having an MS attack and using corticosteroid medication for the last 3 months
- A score of 21 or less on the Montreal Cognitive Assessment (MoCA) test
- Having a mental or organic disability in communicating
- Being diagnosed with any chronic disease other than MS
- Using psychotropic medication or continuing psychotherapy
- Not having or being able to obtain a phone that can connect to the internet
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Intervention group
Participants will implement positive psychological interventions at home for four weeks.
In the first two weeks, they will do the three good things in life exercise, in the third week, they will write a gratitude letter, and in the fourth week, they will write five things they are grateful for.
Participants will be given a guide booklet to write on.
|
An intervention method consisting of three good things in life and gratitude activities was determined for the intervention group.
It will take four weeks.
Three good deeds will be held for two weeks, and gratitude activities will be held for the last two weeks.
Participants will record the interventions on a prepared booklet.
|
|
Placebo Comparator: Kontrol group
Control group participants will practice writing their daily routines for four weeks.
They will write a few sentences about the nutrition routine in the first week, the hygiene routine in the second week, the sleeping routine in the third week, and the shopping routine in the fourth week.
Participants will be given a guide booklet for the writing exercise.
|
An activity was planned for the control group participants to write their daily routines.
They will write down their sleep, nutrition, hygiene and shopping routines, which will be different each week for four weeks.
Control group participants will also be given a booklet to write on.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Multiple Sclerosis Quality of Life Scale (MSQOL)-54
Time Frame: six month
|
It was developed by Vickrey, Hays, Harooni, Myers, and Ellison (1995).
The scale consists of 2 main groups, composite physical health (BFS) and composite mental health (BMS), 12 subgroups and 2 independent items.
The reliability coefficients of the scale were found to be between 0.75-0.96,
and the test-retest reliability coefficients were found to be between 0.66-0.96.
BFS and BMS scores, the two main groups of the MSQOL-54 scale, take a value between 0-100.
A high score from the scale indicates a high quality of life.
|
six month
|
|
PERMA Measuring Tool
Time Frame: six month
|
It was developed by Butler and Kern (2016) to measure well-being levels.
The scale consists of a total of 23 items, 15 items measuring the components of the well-being model and 8 filler items.
Among the filler items in the scale, items 7, 12, 14 and 20 are reverse coded.
There are 3 items in each dimension of the scale, which consists of 15 items.
Sub-dimension scores are calculated by taking the average of the 3 items in the relevant sub-dimension.
The Cronbach Alpha internal consistency coefficient for the total score of the scale is 91.
|
six month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Positive and Negative Mood Scale (PNDS)
Time Frame: six month
|
The Positive and Negative Affect Scale was developed by Watson and colleagues (1988) to assess positive and negative emotion.
There are a total of 20 items in the scale, 10 items for each subscale.
The scale is a five-point Likert scale ranging from 1 (very little to not at all) to 5 (very much).
The score a person gets from the positive or negative emotion subscales varies between 10 and 50.
The internal consistency coefficients of the original form of the scale are .88
for positive emotion and .85 for negative emotion.
|
six month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Nazmiye Yıldırım, Bolu abant Izzet Baysal University
- Principal Investigator: Aliye Yaşayacak, Bolu abant Izzet Baysal University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 15, 2024
Primary Completion (Estimated)
August 30, 2024
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
July 8, 2024
First Submitted That Met QC Criteria
July 8, 2024
First Posted (Actual)
July 15, 2024
Study Record Updates
Last Update Posted (Actual)
August 22, 2024
Last Update Submitted That Met QC Criteria
August 21, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AbantIBU-SBF-AY-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
Clinical Trials on Positive Psychological Intervention Program
-
University of Illinois at Urbana-ChampaignNational Heart, Lung, and Blood Institute (NHLBI)UnknownCardiovascular Risk Factor | Uncontrolled HypertensionUnited States
-
Central South UniversityCompleted
-
University of Illinois at Urbana-ChampaignRosenfeld Heart Foundation GrantUnknownCardiovascular Risk Factor | Uncontrolled HypertensionUnited States
-
Wang XiaweiCompletedIntervention | Psychological Well-BeingChina
-
Tri-Service General HospitalKaohsiung Medical UniversityRecruitingDiabetes Mellitus, Type 2Taiwan
-
University of Illinois at Urbana-ChampaignCompletedMental Health IssueUnited States
-
Lancashire Care NHS Foundation TrustUniversity of ManchesterCompletedDepression, Postpartum | Postnatal Depression in British South Asian WomenUnited Kingdom
-
Universitat Jaume IHospital Provincial de Castellon; PREVI Clinical CenterCompletedEating Disorder | Daily ActivitiesSpain
-
Eskisehir Osmangazi UniversityNot yet recruitingPediatric Cancer | Resilience, Psychological | Mobile Application | Coping | Adolescent Cancer | Pediatric NursingTurkey (Türkiye)